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Brief Definit ive Report
Hematopoietic stem cells (HSCs) are on top of 
the hierarchically organized hematopoietic sys-
tem as they have the ability to long-term self-
renew while giving rise to progeny that can 
generate all mature blood cell types throughout 
adult life (Chao et al., 2008; Trumpp et al., 2010; 
Doulatov et al., 2012). Given that several hema-
topoietic diseases are only curable by allogenic 
HSC transplantation, extensive effort is currently 
focused on understanding the mechanisms by 
which HSCs maintain their self-renewal and 
multipotent properties after transplantation into 
conditioned recipients to be able to robustly re-
constitute the hematopoietic system.
During homeostasis the most primitive HSCs 
reside in a dormant state while the majority of 
HSCs are slowly cycling (Sudo et al., 2000; 
Wilson et al., 2008; Foudi et al., 2009; Trumpp 
et al., 2010). The different HSC populations reside 
in specialized BM niches comprised of different 
hematopoietic and stromal cell types control-
ling HSC cycling, self-renewal, and differentiation 
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The serine protease granzyme B (GzmB) is stored in the granules of cytotoxic T and NK cells 
and facilitates immune-mediated destruction of virus-infected cells. In this study, we use 
genetic tools to report novel roles for GzmB as an important regulator of hematopoietic 
stem cell (HSC) function in response to stress. HSCs lacking the GzmB gene show 
improved bone marrow (BM) reconstitution associated with increased HSC proliferation 
and mitochondrial activity. In addition, recipients deficient in GzmB support superior 
engraftment of wild-type HSCs compared with hosts with normal BM niches. Stimulation 
of mice with lipopolysaccharide strongly induced GzmB protein expression in HSCs, which 
was mediated by the TLR4–TRIF–p65 NF-B pathway. This is associated with increased 
cell death and GzmB secretion into the BM environment, suggesting an extracellular role 
of GzmB in modulating HSC niches. Moreover, treatment with the chemotherapeutic 
agent 5-fluorouracil (5-FU) also induces GzmB production in HSCs. In this situation 
GzmB is not secreted, but instead causes cell-autonomous apoptosis. Accordingly, GzmB-
deficient mice are more resistant to serial 5-FU treatments. Collectively, these results 
identify GzmB as a negative regulator of HSC function that is induced by stress and 
chemotherapy in both HSCs and their niches. Blockade of GzmB production may help to 
improve hematopoiesis in various situations of BM stress.
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expressed in lymphoid cells but is expressed only at low 
levels in either HSCs or multipotent progenitor population 1 
(MPP1) cells (Fig. 1 A and Table S1). Within the stromal com-
partment, the mesenchymal stromal cells express the highest 
level of GzmB mRNA and protein (Fig. 1 B and not de-
picted). GzmB/ mice showed normal marrow cellularity 
and morphology (not depicted) and normal frequencies of 
LSK, MPP1, and HSC populations when compared with WT 
controls (Fig. 1 C). Analysis of the progenitor populations re-
vealed increased common myeloid progenitor and decreased 
common lymphoid progenitor frequency in mutant mice 
(Fig. 1 D and not depicted). Accordingly, a significant increase 
in myeloid cells in the BM of GzmB/ mice was notable 
(Fig. 1 E). To rule out the possibility that other granzymes 
could compensate for the lack of GzmB, the phenotype of 
GzmA/B/ double KO (DKO) was examined (Simon et al., 
1997). GzmA expression in the hematopoietic system is 
largely restricted to lymphoid cells and not detected in HSCs 
and MPP1 (not depicted), and overall, no difference between 
DKO and GzmB/ mice in the hematopoietic system has 
been observed (not depicted). Given the putative extracellular 
roles of GzmB, we analyzed mobilization of GzmB-deficient 
HSCs; however, G-CSF–induced mobilization was unaffected 
in both GzmB/ and DKO mice in comparison with con-
trols, as assessed by the number of LSKs in the peripheral 
blood and CFU in BM, blood, and spleens (not depicted).
The function of HSCs is closely related to their prolifera-
tion status. Analysis of GzmB-deficient HSCs revealed that 
they are less quiescent and are more actively cycling, as shown 
by a significant decrease of HSCs in G0 (Ki67; Fig. 1 F). In 
summary, we observe that the hematopoietic compartment of 
adult GzmB/ mice show only minor alterations during 
homeostasis, although the balance between HSC quiescence 
and cycling is significantly disturbed.
GzmB/ HSCs show increased reconstitution ability  
in competitive BM transplantations
To determine the reconstitution capability of GzmB/ HSCs, 
competitive repopulating assays were performed comparing 
engraftment of GzmB/ with control BM cells. As early as 
4 wk after transplantation, 75.47% (±4.63) of the total myeloid 
and 62.27% (±2.14) of T cell populations in the peripheral 
blood were of GzmB/ origin (Fig. 1, G and H), and simi-
larly, GzmB/ HSCs had largely outcompeted WT HSCs in 
the recipient BM at 16 wk (Fig. 1 I). The competitive advan-
tage of mutant HSCs was even more prominent in secondary 
BM transplantations (Fig. 1 J). The enhanced engraftment of 
GzmB/ HSCs was not caused by improved homing ability 
(not depicted). In contrast, limiting dilution assays (LDAs) re-
vealed a more than fourfold increase of functional HSCs in 
GzmB/ mice compared with controls (Table 1). Collec-
tively, these results suggest that GzmB-deficient mice harbor 
an increased number of repopulating functional HSCs, provid-
ing an explanation for their superior performance in the com-
petitive setting.
(Morrison and Spradling, 2008; Wilson et al., 2008; Méndez-
Ferrer et al., 2009; Ehninger and Trumpp, 2011). Several stimuli 
have been shown to activate HSCs in vivo, including the chemo-
therapeutic agent 5-fluorouracil (5-FU; Randall and Weissman, 
1997; Venezia et al., 2004) and the cytokines G-CSF (Wilson 
et al., 2008) and IFN- and IFN- (Essers et al., 2009; 
Baldridge et al., 2010). Recently, sublethal doses of LPS have 
also been shown to induce HSC and progenitor proliferation 
in vivo (Chen et al., 2010; Scumpia et al., 2010; Esplin et al., 
2011; Takizawa et al., 2011), suggesting that bacterial and viral 
infections can lead to HSC activation.
Our laboratory has previously shown that Myc oncopro-
teins are crucial regulators of hematopoiesis (Wilson et al., 
2004; Laurenti et al., 2008, 2009). Deletion of both c-myc and 
N-myc alleles cause rapid severe BM failure associated with 
apoptosis of all hematopoietic cell types except dormant HSCs 
(Laurenti et al., 2008). Mechanistically, c-Myc– and N-Myc–
deficient HSCs showed a global reduction in ribosome bio-
genesis and a striking 150-fold increase in granzyme B (GzmB) 
transcripts preceding progenitor apoptosis (Laurenti et al., 2008, 
2009). These data raise the possibility that high expression of 
cytoplasmic GzmB protein is the apoptotic mechanism leading 
to HSC death in response to loss of Myc activity (Laurenti 
et al., 2008).
Members of the granzyme family of cytotoxic serine pro-
teases are released by cytoplasmic granules within NK and cy-
totoxic T cells to induce apoptotic cell death of viral infected 
cells or tumor cells. There are 11 known granzymes in mice 
and 5 in humans divided into three clusters (Grossman et al., 
2003; Boivin et al., 2009). GzmA and GzmB are the most abun-
dant ones causing apoptosis by various pathways, although 
the role of GzmA in apoptosis has become controversial. Both 
GzmA and GzmB KO mice are healthy and fertile but present 
susceptibility to ectromelia infection (Müllbacher et al., 1999). 
The serine protease GzmB is known to cleave and activate sev-
eral proapoptotic proteins in response to infection by the per-
forin-dependent cytotoxic response pathway (Chowdhury and 
Lieberman, 2008). Its function has been well established in the 
adaptive immune system in mechanisms involved in graft-
versus-host disease (Graubert et al., 1996, 1997), control of viral 
infections (Müllbacher et al., 1999), and tumor clearance (Cao 
et al., 2007). In addition, extracellular roles including cytokine 
modulation have also been suggested for granzymes (Boivin 
et al., 2009; Froelich et al., 2009). Although the function of 
GzmB in NK and cytotoxic T cells is well described, it has so 
far not been reported to play a role in regulating HSC biology. 
Following up on our unexpected finding that HSCs can ex-
press high levels of GzmB in vivo (Laurenti et al., 2008), we 
used genetic tools to investigate the role of GzmB in HSC 
function during homeostasis and in response to BM stress.
RESULTS AND DISCUSSION
GzmB-deficient mice have normal hematopoiesis
To investigate the role of GzmB in HSCs and progenitors, we 
analyzed its expression in hematopoietic and stromal cells of 
the BM. During homeostatic conditions, GzmB is robustly 
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et al., 2012). Possible mechanisms to explain the phenotype of 
GzmB/ HSCs could be protection from ageing and senes-
cence, increased metabolism, and lack of a fail-safe mechanism 
to halt proliferation uncoupled from self-renewal capacity.
A GzmB-deficient microenvironment promotes  
proliferation and improves HSC function
The cycling differences of GzmB/ HSCs could be exclu-
sively cell autonomous or also be mediated by cell-extrinsic 
cues derived from the microenvironment. In agreement with 
our data in Fig. 1 (G–I), GzmB-deficient HSCs out-competed 
WT HSCs if transplanted at a 1:1 ratio into a WT microenvi-
ronment (Fig. 2 A). However, the cell cycle behavior of mutant 
HSCs in this setting is indistinguishable from control HSCs 
(Fig. 2 B). Although here GzmB-deficient HSCs are growing 
in a WT microenvironment, both compartments lack this gene 
To date, only a small number of genetic mutants have been 
identified that show improved HSC function in vivo (Rossi 
et al., 2012). Examples are mutants for Lnk (Ema et al., 2005), 
DNMT3a (Challen et al., 2012), or TNF receptors (Pronk et al., 
2011). Remarkably, our experiments demonstrate that GzmB 
is one of the few known proteins suppressing HSC function 
under stress conditions, such as reconstitution after lethal irra-
diation. One reason for the positive effect observed in GzmB-
deficient cells may be an increased resistance to stress-induced 
cell death. It has recently been shown that activation of the in-
trinsic apoptosis pathway occurs during transplantation, leading 
to a relevant loss of HSCs (Labi et al., 2013). Moreover, our re-
sults show that GzmB-deficient HSCs are more proliferative 
compared with normal HSCs. This is remarkable as increased 
HSC cycling typically goes along with loss of self-renewal 
and subsequent stem cell exhaustion (Wilson et al., 2009; Rossi 
Figure 1. GzmB/ HSCs are more proliferative and show a superior reconstitution capacity because of an increase in functional HSCs. 
Cell surface marker definition of all cell populations is indicated in Table S1. (A and B) GzmB mRNA expression levels were assessed by RT-PCR in he-
matopoietic cells (A; n = 6) and in HSCs, endothelial cells (EC), mesenchymal stromal cells (MSC), and osteoblasts (OB) during homeostatic conditions 
in WT cells (B; n = 3). Fold change was calculated in relation to HSC GzmB mRNA levels. (C) BM cells from WT or GzmB/ mice were analyzed for the 
indicated cell populations by flow cytometry. (left) Representative FACS plot showing Sca-1 and CD117 (c-Kit) staining of lin cells; box shows gating 
on LSK (LinCD117+Sca1+) cells; (right) calculated frequencies of LSK, MPP1, and HSC cells (n = 6). (D and E) Relative frequencies of the indicated 
progenitor and mature populations in the BM WT and GzmB/ mice, as assessed by flow cytometry (n = 6 each). (F) Cell cycle status of WT(control) 
and GzmB/ HSCs was assessed by Ki67/Hoechst staining. The left panel shows a representative flow cytometry plot, and the right panel shows the 
quantification of data (n = 6). (G) CD45.1+ WT BM cells were mixed in a 1:1 ratio either with CD45.2+ WT or GzmB/ BM cells. The relative contribu-
tion of donor-derived GzmB/ CD45.2 and WT CD45.1 BM cells to T, B, and myeloid (My) cells in the circulation was assessed 16 wk after transplan-
tation (n = 6). Gray dashed line indicates 50% reconstitution. (H) Frequency of WT and GzmB/ myeloid cells in the circulation was assessed at 4 and 
16 wk after transplantation (n = 6). (I) CD45.2+ GzmB/ (red) or WT (blue) BM cells were mixed with CD45.1+ WT HSCs and injected into WT recipient 
mice, and the frequency of CD45.2 donor cells in the BM was assessed by flow cytometry (n > 9). Graphs in A–I are representative of three indepen-
dent experiments. (J) CD45.2+ GzmB/ and CD45.1+ WT HSCs from primary recipients were injected into secondary hosts, and their frequency after 
primary and secondary BM transplantation was assessed by flow cytometry compared with the input (n = 6). Results in all panels represent means ± 
SEM of at least two experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.
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1993; Birdsall et al., 2004; Buzza et al., 2005) or receptors im-
portant for cell migration and proliferation such as FGFR1 and 
Notch1 (van Tetering et al., 2011; Chioni and Grose, 2012).
Because a GzmB-deficient microenvironment enhances 
HSC function in vivo, we analyzed the BM niche with respect 
to stromal cell types or presence of circulating cytokines. This 
revealed a mild decrease in endothelial cells (Fig. 2 F) and lower 
levels of the immune modulatory cytokines IL12, IFN-, and 
VEGF- (Fig. 2 G). In summary, the results show that altera-
tions within the GzmB/ BM milieu facilitate HSC prolifera-
tion and improve the functional capacity of HSCs, suggesting 
that GzmB influences HSCs not only in an intrinsic but also in 
an extrinsic manner.
GzmB/ HSCs show increased cell cycle  
and mitochondrial activity in vivo
To further elucidate the molecular mechanisms involved in 
the improved function of GzmB-deficient HSCs, their gene 
expression profile was determined. Gene set enrichment 
analysis (GSEA) indicated that cell cycle G1-phase genes are 
enriched in GzmB/ HSCs (Fig. 2 H), in agreement with 
the increased proliferation of BM HSCs during homeostatic 
conditions. GzmB/ HSCs express slightly lower mRNA 
levels of p19INK4d (Fig. 2 I), an inhibitor of CDK4/CDK6 and 
early G1-S transition which has also been implicated in se-
nescence and protection from DNA damage and apoptosis 
(Stepanova and Sorrentino, 2005; Oguro et al., 2006). Addi-
tionally, functional annotation (DAVID) showed that GzmB/ 
HSCs are enriched for mitochondrial genes (not depicted). 
Indeed, mitochondrial mass/activity was increased about three-
fold in GzmB/ HSCs (Fig. 2 J), suggesting that GzmB is a 
negative regulator of mitochondrial activity in homeostatic 
HSCs. The increased mitochondrial mass in mutant HSCs is 
consistent with their increased cycling activity. Interestingly, 
in cytotoxic T cells, GzmB contributes to mitochondrial 
damage during the apoptotic response and is involved in Bcl2 
inhibition, cytochrome c release, mitochondria swelling, trans-
membrane potential loss, and reactive oxygen species produc-
tion (Chowdhury and Lieberman, 2008). Therefore, the lack 
of GzmB could potentially protect HSCs from mitochondrial 
injury in response to stress, allowing them to perform better 
in BM reconstitution assays after lethal irradiation.
LPS induces GzmB in HSCs and progenitors in vivo
Next we asked whether other stress stimuli such as bacterial 
or viral infections would also trigger a GzmB response in vivo. 
LPS is the major component of the outer membrane of Gram-
negative bacteria and binds to the TLR4–MD2 receptor 
complex, which leads to the production of inflammatory 
cytokines (Hennessy et al., 2010). High-dose LPS treatment 
of mice is often used as a model to study endotoxic shock 
(Akira and Takeda, 2004). Here we treated mice with low 
doses of LPS to mimic common bacterial infections, which 
can also lead to HSC activation (Takizawa et al., 2011). LPS 
treatment induced a robust 10-fold increase in GzmB but not 
GzmA transcripts in HSCs (Fig. 3 A). GzmB expression was 
in GzmB mutant animals (Fig. 1 F). These results indicate that 
the augmented HSC proliferation observed in GzmB mutant 
mice is likely caused by the conditions present in GzmB-
deficient BM niches.
Given the known role of GzmB in apoptosis, we reasoned 
that in a WT microenvironment HSCs are more susceptible to 
proapoptotic signals. To address this possibility, we have mea-
sured cleaved caspase-3 in long-term transplanted HSCs (not 
depicted) and mRNA levels of key pro- and antiapoptotic pro-
teins in HSCs 3 wk after transplantation; however, no changes 
could be detected (not depicted). Nevertheless, because of tech-
nical constraints (e.g., fast in vivo dead cell clearance), we cannot 
formally rule out the possibility that GzmB-mediated apoptosis 
may play a role in the maintenance of engrafted HSCs.
To further investigate the role of GzmB in the BM niche, 
primary and secondary BM reconstitution assays were per-
formed. First, WT total BM cells (WT) were transplanted into 
either WT (control) or GzmB/ (KO) recipient mice. We ob-
served that WT LSK cells in the GzmB-deficient BM setting 
(WT(KO)) were less quiescent and more proliferative com-
pared with WT cells transplanted into a WT control niche 
(WT(control); Fig. 2 C). Interestingly, in competitive secondary 
transplantations, MPP1 and HSCs derived from the WT(KO) 
setting represented 31.26% (±3.11) of the secondary recipient 
BM, whereas HSCs derived from the WT(control) setting only 
contributed to 4.79% (±0.86) of total BM cells (Fig. 2 D). Sim-
ilar results were obtained analyzing the myeloid progeny in the 
peripheral blood of the recipient mice (Fig. 2 E). These results 
suggest that the GzmB-deficient microenvironment enhances 
the expansion and engraftment capacity of normal HSCs. Thus, 
GzmB deficiency not only displayed a positive effect on the 
ability of HSCs to engraft, but a GzmB-deficient microenvi-
ronment was also beneficial to normal HSC engraftment and 
reconstitution of the hematopoietic system in a transplant set-
ting. Possibly, GzmB might exert a negative effect on HSCs by 
modulating cytokine function by proteolysis (Boivin et al., 
2012), cleaving extracellular matrix components (Froelich et al., 
Table 1. LDA








Control 1,000 3/10 1 in 26,559  
(54,453–12,954)Control 10,000 4/10
Control 100,000 9/10
GzmB/ 1,000 2/10 1 in 5,354  
(10,164–2,820)GzmB/ 10,000 10/12
GzmB/ 100,000 10/10
Serially diluted control or GzmB/ total BM cells were transplanted with 
supportive WT total BM cells, and HSC engraftment was quantified 14 wk after 
transplantation. Frequency of HSCs was calculated, according to Poisson statistics 
using ELDA software, from combined results of two independent experiments with 
n = 10/group (two-tailed Student’s t test; P = 0.026). Positive: >1% engraftment 
BM (LSK SLAM). CI, confidence interval.
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Figure 2. GzmB-deficient BM microenvironment promotes stem and progenitor cell proliferation and improves HSC function. (A and B) CD45.2 
GzmB/ and WT CD45.1/2 (control) BM was transplanted into WT CD45.1 recipient mice. (A) Engraftment of HSCs was assessed by flow cytom-
etry (black; n = 7). (B) The cell cycle status of transplanted WT CD45.1/2 and GzmB/ CD45.2 HSCs was assessed by Ki67/Hoechst staining. The 
left panel shows representative flow cytometry plots, and the right panel shows quantification from n = 7 mice. (C) Reverse chimeras were gener-
ated by transplanting 106 CD45.1/2 WT BM cells into WT (WT(control)) or GzmB-deficient mice WT(KO) (n = 7). Percentage of LSK cells in G0 phase 
of the cell cycle was assessed by Ki67/Hoechst staining 16 wk after transplantation (n = 7). (D) Total BM was harvested from the primary recipi-
ents described in C, mixed at a 1:1 ratio with fresh CD45.1 WT total BM, and injected into lethally irradiated secondary CD45.1 WT recipients. LSK 
SLAM cells (CD45.1/2) were quantified in secondary recipients (CD45.1) by flow cytometry 16 wk after transplantation (n = 7). Representative flow 
cytometry contour plots (left) and quantification from n = 7 mice/group (right) are shown. (E) The frequency of Gr1+CD11b+ myeloid progeny was 
assessed by flow cytometry in the reverse chimeras generated in D (n = 7). (F) Frequency of the indicated BM stromal cell types in control and 
GzmB/ mice was assessed by flow cytometry (n = 3). (G) Protein levels of IL12, IFN-, and VEGF were measured in the BM of WT and GzmB/ 
mice by cytokine array (n = 3). (H) HSCs were isolated from GzmB-deficient mice, and RNA was subject to microarray analysis. A GSEA plot of cell 
cycle G1-phase genes is shown. P < 0.05 and normalized enrichment score (NES) = 1.77. Positively (red) and negatively (blue) correlated genes are 
shown. (I) HSCs were purified from WT and GzmB/ mice, and Cdkn2d (p19) mRNA levels were measured by RT-PCR (n = 6). (J) Mitochondrial 
mass analysis of homeostatic WT and GzmB/ HSCs as assessed by MitoTracker staining (n = 6). MFI, mean fluorescence intensity. Data in A–G, I,  
and J represent means ± SEM of two independent experiments. *, P < 0.05; ***, P < 0.001; and ****, P < 0.0001.
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activation in HSCs in vivo (Fig. 3 I, left and right). These data 
provide evidence that GzmB expression in HSCs is at least 
partially dependent on LPS-mediated NF-B activation. Al-
though the data are consistent with the view that LPS-TRIF 
signaling within HSCs leads to NF-B activation, it remains 
possible that myeloid cells may serve as an intermediate that 
trigger NF-B activity in HSCs.
Our data suggest that LPS-induced GzmB expression 
could mediate cell-autonomous apoptotic mechanisms in 
HSCs. GzmB deficiency improved the resistance of mice 
to septic shock induced by LPS (Metkar et al., 2008), and pa-
tients undergoing sepsis showed an increase in circulating lev-
els of GzmA and GzmB in the blood (Spaeny-Dekking et al., 
1998; Lauw et al., 2000), demonstrating a role for GzmB in 
the inflammatory response to septic shock–induced cytotox-
icity. Indeed, 23.73% (±5.34) of the LPS-stimulated HSCs 
showed an increase in active cleaved Caspase-3, whereas this 
induction was totally suppressed in TRIF/ HSCs and par-
tially suppressed in the GzmB-deficient HSCs (Fig. 3 J). To 
functionally explore whether GzmB mediates the deleterious 
effects of LPS on HSCs and progenitors, we isolated LPS-
stimulated CD45.2 WT or GzmB/ BM HSCs and per-
formed 1:1 competitive transplantations with untreated 
CD45.1/2 WT total BM into CD45.1 WT recipients. As 
shown in Fig. 3 K, pretreatment with LPS significantly re-
duces the competitiveness of HSCs in this experiment from 
33.20 ± 7.2% to 10.71 ± 5.3%. Strikingly, the negative effect 
of LPS was not observed in the GzmB-deficient setting, as 
neither HSCs (Fig. 3 K) nor differentiated hematopoietic cells 
showed a statistically significant difference in the chimerism 
compared with the PBS-treated controls (Fig. 3 L). In agree-
ment, the colony-forming ability after in vivo LPS treatment 
was significantly reduced in a WT but not GzmB mutant set-
ting (Fig. 3 M). In summary, LPS treatment negatively affects 
HSC and progenitor function in vivo and in vitro, which is 
rescued in the absence of induced GzmB.
GzmB deficiency confers resistance to serial 5-FU challenge
Elimination of proliferative myeloid cells by the chemothera-
peutic drug 5-FU leads to activation of HSCs, which is trig-
gered by an as yet undefined feedback loop (Randall and 
Weissman, 1997; Venezia et al., 2004; Wilson et al., 2008). A 
single dose of 5-FU triggered a strong induction of GzmB pro-
tein expression in HSCs (Fig. 4 A), suggesting that chemothera-
peutic BM stress also triggers GzmB expression in HSCs. 
Interestingly, and contrary to the LPS response, no significant 
secretion of GzmB into the BM was observed upon 5-FU treat-
ment (Fig. 4 B). This finding correlates with the subcellular 
localization of GzmB proteins in 5-FU– and LPS-treated mice. 
Although GzmB is stored in distinct granules upon LPS treat-
ment, it is diffusely distributed in the cytoplasm of BM cells in 
response to 5-FU treatment (Fig. 4 C). To further address the 
contribution of extracellular GzmB in the regulation of the 
hematopoietic BM niche in response to stress, we administered 
5-FU once every week (Cheng et al., 2000; Essers et al., 2009) 
to cohorts of control and GzmB/ mice and monitored them 
also induced in progenitors and, as expected, also in T and B cells 
(Fig. 3 B). Not only mRNA, but also GzmB protein was 
increased in HSCs (Fig. 3 C), and the levels remained high for 
at least 24 h (Fig. 3 D). Our results show that in response to 
LPS, and thus bacterial infections, GzmB is not only induced 
in lymphocytes, but also in HSCs and progenitors in vivo.
In activated T and NK cells, GzmB is compartmentalized 
within cytoplasmic granules to protect the host cells from 
immediate apoptosis (Chowdhury and Lieberman, 2008). In 
analogy, GzmB was also localized in cytoplasmic granules in 
LPS-stimulated HSCs (Fig. 3 E), consistent with the hypoth-
esis that this molecule is secreted into the BM microenviron-
ment upon LPS stimulation by HSCs and its progeny. Indeed, 
the levels of extracellular GzmB in the BM were threefold 
increased after LPS treatment in vivo (Fig. 3 F). These data in-
dicate that GzmB could act as a niche remodeling protease 
secreted by HSCs and progeny to alter inflammatory cues by 
modulating cytokine levels in response to LPS. In support of 
this, we found lower levels of IL-12 in the BM milieu of 
GzmB-deficient mice (not depicted), a cytokine know to 
promote immune defense by inducing the T helper 1 pheno-
type, enhancing NK cell cytotoxicity and IFN- production 
(Trinchieri, 2003). Further studies are required to evaluate the 
kinetics, release, and processing of these cytokines related to 
extracellular GzmB function upon stress.
GzmB expression in HSCs is dependent  
on TLR4–TRIF–NF-B signaling
To further dissect the mechanisms involved in LPS-induced 
GzmB expression in HSCs, we used KO models, including the 
ones for the LPS receptor TLR4 and the adaptor proteins 
MyD88 and TRIF (Hennessy et al., 2010). LPS-dependent 
GzmB induction was completely abrogated in the TLR4/ 
and TRIF/ mice and partially reduced in MyD88/ mice 
(Fig. 3 G). Interestingly, neither lack of IL6 production nor the 
abrogation of IFN- response to LPS (Baldridge et al., 2011) 
affected the increased GzmB expression in LPS-stressed BM 
HSCs (not depicted). Together these results suggest that GzmB 
expression in HSCs is dependent on LPS-TLR4–mediated sig-
naling in HSCs and/or myeloid cells but independent of the 
cytokines IL6 and type-1 IFNs.
Expression of human GzmB in NK cells can be regulated 
by NF-B signaling (Huang et al., 2006), which is also known 
as an important component downstream of LPS signaling in 
myeloid cells in vivo (Kawai and Akira, 2006). We observed a 
strong correlation between GzmB expression and NF-B ef-
fector p65 (Rel A) induction in HSCs. At 12 h after LPS treat-
ment, 80.97% (±3.84) of HSCs were positive for both p65 and 
GzmB, which was sustained at later time points (not depicted). 
Moreover, coexpression of GzmB and the nuclear active form 
of p65 (p65pS536) was found in 92.87 ± 3.02% of HSCs after 
LPS treatment, whereas virtually no such cells were detectable 
in control animals (Fig. 3 H). Pretreatment of mice with pyrro-
lidine dithiocarbamate (PDTC), an antioxidant known to in-
hibit p65 accumulation in the nucleus (Ziegler-Heitbrock, 
1993), significantly attenuated the expression of GzmB and p65 
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Figure 3. LPS-induced GzmB expression in HSCs is dependent on TLR4–TRIF–NF-B signaling, is secreted, and impairs HSC function in vivo. 
WT mice were injected with 5 µg LPS i.p. or PBS, and BM was isolated 16 h later. (A and B) GzmA and GzmB mRNA levels in HSCs (A; n = 6) and GzmB mRNA 
in BM hematopoietic cells (B; n = 6) were measured by RT-PCR. (C) Representative flow cytometry histogram showing GzmB protein expression in HSCs from 
mice injected with LPS or PBS (n = 3). (D) GzmB expression in HSCs was measured by flow cytometry at the indicated times after LPS treatment (n = 6). (E) LSK 
SLAM cells were purified from in vivo LPS-stimulated WT mice for 16 h, and GzmB cellular localization was assessed by immunofluorescence using anti-GzmB 
antibodies and DAPI nuclear staining (n = 4). Bars, 5 µm. (F–H) Mice of the indicated genotype were injected with LPS or PBS as in A (n = 6). (F) Extracellular 
GzmB (pg/ml) in the BM niche was measured by ELISA. (G) Percentage of GzmB-expressing HSCs (GzmB+) in TLR4/, TRIF/, and MyD88/ mice was as-
sessed by flow cytometry. (H) Representative flow cytometry contour plot showing p65pS536 and GzmB expression in HSCs from WT mice 16 h after LPS 
stimulation. (I) WT mice were pretreated or not with 10 mg/kg PDTC i.p., followed by LPS 10 h later. GzmB and p65pS536 expression in HSCs was measured by 
flow cytometry 16 h after LPS injection (n = 6). (J) WT, TRIF/, or GzmB/ mice were injected with LPS or PBS as in A, and levels of active caspase-3  
(c-Casp3) were measured in HSCs by flow cytometry (n = 6). (K) CD45.2 GzmB/ or WT mice were injected with LPS or PBS, and HSCs were purified 
16 h later, mixed with 106 WT CD45.1/2 BM cells, and injected i.v. into lethally irradiated WT recipients. HSC engraftment was measured by flow cytometry 
16 wk after transplant (n = 6). (L) Frequency of the indicated hematopoietic cell types in the mice described in K. (M) GzmB/ and WT mice were treated 
with LPS or PBS as in A, and CFUs of total BM cells were assessed. Three plates per point were scored per experiment, and cells were pooled from three 
different mice. Data represent means ± SEM of at least three (A–F) or two (G–M) independent experiments. *, P < 0.05; **, P < 0.01; and ***, P < 0.001.
for survival. Interestingly, GzmB-deficient mice showed a bet-
ter survival under these harsh conditions despite the increased 
proliferative status of their HSCs. This is consistent with an 
improved chemoresistance of mutants compared with control 
mice, which is likely related to a decreased apoptotic response 
(Fig. 4 D). Strikingly, the cellular localization of GzmB upon 
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uses GzmB as a cell-autonomous cytotoxic protein leading to 
intrinsic hematopoietic cell death, similarly to the intrinsic 
cytotoxic mechanism observed in HSCs lacking c-Myc and 
N-Myc (Laurenti et al., 2008). Finally, our data suggest that 
both mechanisms of GzmB function may be used to either 
improve HSC engraftment in patients or for treatment of 
chronic inflammatory situations such as those observed in 
hematological malignancies.
MATERIALS AND METHODS
Mice. 8–12-wk-old female C57BL/6 mice purchased from Harlan Labo-
ratories were used throughout the study. The following mouse lines were 
used: GzmB/ (provided by T. Ley, Washington University in St. Louis, 
St. Louis, MO; Graubert et al., 1996); IFNRA/ (Müller et al., 1994), 
TLR4/ (Poltorak et al., 1998), TRIF/ (provided by M. Pasparakis; 
Ermolaeva et al., 2008), Myd88/ (Adachi et al., 1998), and p65-GFP 
(De Lorenzi et al., 2009). All animal protocols were approved by the Regier-
ungspräsidium Karlsruhe Landwirtschaft, Ländlicher Raum, Veterinär- und 
Lebensmittelwesen of Baden-Württemberg (G-150-12) and according to 
the German laws for animal protection.
In vivo LPS, PDTC, and 5-FU treatment. Mice were injected i.p. with 
PBS or 5 µg LPS from Escherichia coli (Sigma-Aldrich) once and were ana-
lyzed 16 h after the injection (unless otherwise indicated). Mice were in-
jected i.p. with 10 mg/kg PDTC (Sigma-Aldrich). For 5-FU challenge, mice 
were injected i.p. with 150 mg/kg 5-FU (Sigma-Aldrich) once a week, and 
animal survival was recorded.
Isolation of BM cells. For the isolation of total BM, mice were sacrificed 
and the BM was extracted under sterile conditions by crushing the bones in 
RPMI + 2% FCS using a mortar and pestle. The BM suspension was filtered 
through a 40-µm cell strainer and centrifuged for 5 min at 1,500 rpm. Sub-
sequently, the cell pellet was resuspended in 1 ml ACK lysing buffer (Lonza) 
and incubated for 5 min at room temperature to allow lysis of red blood cells. 
Cells were washed in 5 ml RMPI + 2% FCS, centrifuged, and resuspended 
5-FU treatment strongly resembles the cytotoxic distribution 
pattern observed in the c-Myc/N-Myc DKO HSCs (Laurenti 
et al., 2008). To address whether there is a contribution of the 
niche cells to the observed HSC loss in response to 5-FU chal-
lenge, we examined the expression of GzmB in stromal cells. 
However, GzmB mRNA is down-regulated and barely detect-
able in such conditions (not depicted). Collectively, these data 
suggest that cytoplasmic GzmB expression contributes to the 
cytotoxic effects of 5-FU and its inhibition significantly attenu-
ates its hematotoxic effects. This supports the hypothesis that in 
both stress scenarios, LPS and 5-FU, GzmB executes an intrin-
sic cytotoxic function and may function as a fail-safe mecha-
nism to eliminate damaged HSCs in vivo. Future studies are 
needed to elucidate its possible function and its therapeutic 
value as a target in either augmenting myeloablative therapy in 
leukemias or attenuating 5-FU–mediated BM side effects in 
the treatment of nonhematological diseases.
In summary, our finding that GzmB deficiency increased 
HSC function and likely self-renewal associated with in-
creased mitochondrial function is of significant relevance for 
further studies, which should address its role in initiation and 
progression of leukemias. Moreover, our results suggest that 
under stress conditions, there might be two different mecha-
nisms by which GzmB regulates HSC function (Fig. S1). The 
first mechanism, mediated by LPS, involves GzmB expression 
in granules and GzmB secretion into the BM niche by HSCs 
and its progeny, including myeloid and lymphoid cells. In this 
scenario, GzmB may act by remodeling extracellular matrix 
proteins or processing cytokines, similar to its proposed roles 
in chronic inflammatory diseases (Hendel et al., 2010) and in 
promoting aggressive T-ALL (Winrow et al., 2005). The sec-
ond mode of action, as observed in response to 5-FU treatment, 
Figure 4. GzmB deficiency increases 5-FU chemo-
resistance in vivo. (A) WT and GzmB/ mice were 
treated with a single dose of 5-FU, and LSK SLAM cells 
were quantified after 4 d. (left) Representative flow cy-
tometry histogram; (right) bar graph showing quantita-
tive data from n = 3 mice/group. (B and C) WT mice (n = 
3) were injected with a single dose of 5-FU or LPS, and 
BM was analyzed at 4 d and 16 h, respectively. (B) GzmB 
secreted in the BM was assessed by dot blot (left) and 
quantified in n = 3 mice/group (right). (C) GzmB expres-
sion in the BM was assessed by immunofluorescence 
staining with anti-GzmB antibodies and DAPI nuclear 
stain (n = 3). Bars, 10 µm. (D) GzmB/ and WT mice 
(n = 7/group) were injected weekly with 5-FU, and survival 
was monitored. Data in graphs represent means ± SEM 
of three independent experiments. *, P < 0.05; **, P < 0.01; 
and ***, P < 0.001.
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Homing assay of hematopoietic progenitor cells. C57BL/6 Ly5.1 mice 
were lethally irradiated (6 Gy) 24 h before transplantation. 6 or 16 h after injec-
tion, BM cells were harvested from femurs stem cells, and progenitors were 
quantified and analyzed by flow cytometry. Homing of hematopoietic progen-
itor cells is calculated relative to the total number of LSK SLAM cells.
GzmB intracellular staining. For FACS analyses, total BM or Lineage-
negative cells were stained for surface markers, and intracellular GzmB pro-
tein was detected with a directly conjugated GzmB-PE or -APC antibody 
(Invitrogen). Mouse IgG1-PE was used as the appropriate IgG control. For 
immunofluorescence assays, Lineage-negative or sorted LSK SLAM cells 
were fixed in 3.7% PFA and then cytospun onto slides. After permeabiliza-
tion in PBS + 0.2% Triton X-100 and blocking with PBS + 15% goat serum, 
the slides were stained overnight with anti–mouse GrB biotinylated antibody 
(R&D Systems) and then for 1 h with SAV–Alexa Fluor 488 or 546. Nuclei 
were counterstained with DAPI.
Cell proliferation assays. Surface staining and intracellular staining of Lin 
BM cells were performed as described in Flow cytometry and cell sorting. 
For Ki67 staining, cells were fixed and permeabilized and further incubated 
with anti–Ki67-FITC or -APC antibody (BD) at 4°C overnight. Hoechst 
33342 was added right before FACS analysis.
Mitochondrial mass. Mitochondrial content was investigated using Mito-
Tracker green FM (Invitrogen). In brief, total BM cells were incubated at 
37°C for 30 min with 50 nM MitoTracker green, washed and resuspended in 
PBS, and analyzed by flow cytometry. As a positive control, cells were treated 
with 1 µM oligomycin for 1 h ex vivo before MitoTracker labeling.
BM histology. Fresh femurs were collected for paraffin blocks or cryosec-
tions. Frozen sections were prepared by the tape transfer method (Section-
Lab Co Ltd). Sections were subjected to hematoxylin and eosin (H&E) 
staining. For immunofluorescence experiments, sections were treated with 
100% ethanol and blocked in 2% horse serum.
Immunohistochemistry. Cytospins from fixed Lin or Lin Sca-1+ c-Kit+ 
CD48 CD150+ (LSK SLAM) sorted cells were prepared by diluting 1–2 × 
104 cells in 100 µl PBS and transferring them into a preconditioned Shandon 
EZ Cytofunnel (Thermo Fisher Scientific) containing a glass microscope 
slide. The cells were spun onto the slide by centrifugation in the Cytospin 4 
(Thermo Fisher Scientific) for 5 min at 1,000 rpm. Subsequently, the cyto-
spins were subjected to immunohistochemical staining. Cells were blocked 
with goat serum + Triton X-100 in PBS for 60 min and then incubated 
overnight at 4°C with GzmB-Biotin (R&D Systems). After three times of 
washing, the respective secondary antibodies were added: streptavidin–Alexa 
Flour 546. After two washing steps, cells were incubated with a 1:500 dilution 
of DAPI for 5 min. After one last washing step, the slides were mounted with 
coverslips using Faramount Aqueous Mounting Medium (Dako). Fluores-
cence microscopy was performed on a Cell Observer or LSM700 using the 
AxioVision software (all Carl Zeiss).
ELISA and cytokine array. Extracellular mouse GzmB was measured in 
an ELISA. In short, supernatant from fresh BM was collected and subjected 
to analysis with the mouse GzmB ELISA Ready-SET-Go! kit (eBioscience) 
or Cytokine array membranes (RayBiotech).
Microarray analysis. Homeostatic and transplanted HSCs were sorted and 
RNA isolated using Arcturus PicoPure (Applied Biosystems), and 2.5 ng of 
total RNA was used for hybridization on Illumina Mouse Sentrix-6 Bead-
Chips. For statistical quantification, permutation testing in GSEA was per-
formed with 1,000 permutations by gene set. Microarray data are deposited 
in the Gene Expression Omnibus under accession no. GSE56574.
Real-time quantitative RT-PCR. Total RNA was extracted from sorted 
HSCs using the Arcturus PicoPure (Applied Biosystems). Complementary 
in up to 5 ml RMPI + 2% FCS. A 1:50 dilution of the cells was counted 
using the Vi-CELL cell viability analyzer (Beckman Coulter).
Lineage depletion. Lineage depletion was performed using the Dynal 
Mouse CD4 Negative Isolation kit (Invitrogen) according to the manual in-
structions. CD4-Bio (eBioscience) was added to lineage antibody mix.
Flow cytometry and cell sorting. For analysis of HSCs by flow cytome-
try, Lin enriched BM cells were stained with antibodies against the follow-
ing surface markers: CD4–PE-Cy7, CD8–PE-Cy7, CD11b–PE-Cy7, CD45R 
(B220)–PE-Cy7, Ter119–PE-Cy7, Gr-1–PE-Cy7, Sca1–APC-Cy7, Sca1–
Alexa Fluor 700, Sca1–Pacific blue, CD117 (c-Kit)-APC, CD117 (c-Kit)–
APC-Cy7, CD117 (c-Kit)–PE, CD150–PE-Cy5, CD48–Pacific blue, 
CD34–Alexa Fluor 700, IL7Ra-PE, and FcyRII/III-APC. All antibody con-
jugates were purchased from eBioscience. Antibodies were diluted in a 1:1 
mix of 2.4G2 blocking buffer and RMPI + 2% FCS. For intracellular stain-
ing, surface-stained cells were fixed with BD Cytofix/Cytoperm for 15 min 
on ice and subsequently permeabilized with BD Perm/Wash. Cells were 
then incubated overnight with anti–human GzmB-PE or -APC (Invitrogen) 
or anti–mouse GzmB-FITC (eBioscience) in combination with either anti–
active Caspase-3–FITC or –PE (BD) or p65pS536 Alexa Fluor 488 (Cell Sig-
naling Technology). Before analysis, the cells were washed and resuspended in 
BD Perm/Wash. Flow cytometry analysis was performed on a BD LSRII 
flow cytometer or a BD LSRFortessa cell analyzer, and cell sorting was exe-
cuted on a BD FACSAria II. FACS data were analyzed with FlowJo software 
(Tree Star).
BM transplantations. For generation of competitive chimeras, mice were 
lethally irradiated with 11–12 Gy split-dose 4 h apart, and BM transplants 
were performed within 24 h by tail vein injection. Engraftment was mea-
sured monthly through facial vein bleed and FACS analysis with CD45.1-
FITC, CD45.2-PB, CD4-PECy7, B220-PE, CD11b-PECy5, Gr1-APC, and 
Ter119-APCCy7. All antibodies were ordered from eBioscience unless oth-
erwise specified.
LDA. Serial dilutions of WT and GzmB/ total BM (CD45.2) were trans-
planted by tail vein injection together with 2.105 supportive total BM cells 
(CD45.1) and transplanted into lethally irradiated WT CD45.1 recipient 
mice. Peripheral blood was analyzed for engraftment at 8 and 12 wk for my-
eloid and lymphoid reconstitution, and HSC engraftment in BM was ana-
lyzed at 14 wk. Mice for which engraftment was <1% were considered 
nonengrafted and were not taken into account for calculation of stem cell 
frequencies. Calculation of stem cell frequencies and statistics was performed 
using ELDA software (Hu and Smyth, 2009).
Cell culture. Lineage-depleted BM cells were seeded in at a density of 1–2 × 
106 cells per well in 500 µl HSC medium. The medium was composed of 
StemPro-34 SFM (Gibco) supplemented with StemPro-34 Nutrient (Gibco), 
100 U/ml Pen/Strep (Sigma-Aldrich), 2 mM l-glutamine (Gibco), 50 ng/ml 
mSCF, 25 ng/ml mTPO, 30 ng/ml Flt3, and 105 U/ml IL-11 (R&D Systems). 
The cells were cultured at 37°C and 5% CO2.
Hematopoietic colony-forming cell assay. Fresh total BM or cultured 
Lin BM cells were counted and diluted to a concentration of 105 cells per 
milliliter in sterile PBS. For duplicates, 260 µl of the cell suspension was 
added to 2.6 ml MethoCult GF M3434, containing recombinant mouse 
SCF, recombinant mouse IL-3, recombinant human IL-6, and recombinant 
human EPO (STEMCELL Technologies). For triplicates, 350 µl of the cell 
suspension was added to 3.5 ml of MethoCult GF M3434. After 7–10 d, the 
dishes were scored for different hematopoietic colonies.
Mobilization assays. Mice were injected with PBS or 300 µg huG-CSF 
(Amgen) for a consecutive 6 d subcutaneously. On day 6, mice were sacri-
ficed, and BM, spleens, and peripheral blood were harvested. Single cell sus-
pensions were analyzed by flow cytometry and stained with Lineage marker, 
Sca-1, and c-Kit.
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used in the real-time RT-PCR were the following: Oaz1 FW, 5-TTTCAGC-
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otherwise specified). For determination of stem cell frequency, Poisson test 
was performed. Statistical significance is indicated by *, P < 0.05; **, P < 0.01; 
***, P < 0.001; and ****, P < 0.0001.
Online supplemental material. Fig. S1 shows a model depicting GzmB 
function in HSCs in response to stress. Table S1 lists cell surface marker phe-
notypes. Online supplemental material is available at http://www.jem.org/ 
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